These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 32380977)

  • 1. Efficacy of andrographolide in not active progressive multiple sclerosis: a prospective exploratory double-blind, parallel-group, randomized, placebo-controlled trial.
    Ciampi E; Uribe-San-Martin R; Cárcamo C; Cruz JP; Reyes A; Reyes D; Pinto C; Vásquez M; Burgos RA; Hancke J
    BMC Neurol; 2020 May; 20(1):173. PubMed ID: 32380977
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Cannabinoid Use in Progressive Inflammatory brain Disease (CUPID) trial: a randomised double-blind placebo-controlled parallel-group multicentre trial and economic evaluation of cannabinoids to slow progression in multiple sclerosis.
    Ball S; Vickery J; Hobart J; Wright D; Green C; Shearer J; Nunn A; Cano MG; MacManus D; Miller D; Mallik S; Zajicek J
    Health Technol Assess; 2015 Feb; 19(12):vii-viii, xxv-xxxi, 1-187. PubMed ID: 25676540
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis (MS-SMART): a phase 2b, multiarm, double-blind, randomised placebo-controlled trial.
    Chataway J; De Angelis F; Connick P; Parker RA; Plantone D; Doshi A; John N; Stutters J; MacManus D; Prados Carrasco F; Barkhof F; Ourselin S; Braisher M; Ross M; Cranswick G; Pavitt SH; Giovannoni G; Gandini Wheeler-Kingshott CA; Hawkins C; Sharrack B; Bastow R; Weir CJ; Stallard N; Chandran S;
    Lancet Neurol; 2020 Mar; 19(3):214-225. PubMed ID: 31981516
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial.
    Lublin F; Miller DH; Freedman MS; Cree BAC; Wolinsky JS; Weiner H; Lubetzki C; Hartung HP; Montalban X; Uitdehaag BMJ; Merschhemke M; Li B; Putzki N; Liu FC; Häring DA; Kappos L;
    Lancet; 2016 Mar; 387(10023):1075-1084. PubMed ID: 26827074
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mitoxantrone: a review of its use in multiple sclerosis.
    Scott LJ; Figgitt DP
    CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Cree BAC; Cutter G; Wolinsky JS; Freedman MS; Comi G; Giovannoni G; Hartung HP; Arnold D; Kuhle J; Block V; Munschauer FE; Sedel F; Lublin FD;
    Lancet Neurol; 2020 Dec; 19(12):988-997. PubMed ID: 33222767
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension.
    Kapoor R; Ho PR; Campbell N; Chang I; Deykin A; Forrestal F; Lucas N; Yu B; Arnold DL; Freedman MS; Goldman MD; Hartung HP; Havrdová EK; Jeffery D; Miller A; Sellebjerg F; Cadavid D; Mikol D; Steiner D;
    Lancet Neurol; 2018 May; 17(5):405-415. PubMed ID: 29545067
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, rationale, and baseline characteristics of the randomized double-blind phase II clinical trial of ibudilast in progressive multiple sclerosis.
    Fox RJ; Coffey CS; Cudkowicz ME; Gleason T; Goodman A; Klawiter EC; Matsuda K; McGovern M; Conwit R; Naismith R; Ashokkumar A; Bermel R; Ecklund D; Koepp M; Long J; Natarajan S; Ramachandran S; Skaramagas T; Thornell B; Yankey J; Agius M; Bashir K; Cohen B; Coyle P; Delgado S; Dewitt D; Flores A; Giesser B; Goldman M; Jubelt B; Lava N; Lynch S; Miravalle A; Moses H; Ontaneda D; Perumal J; Racke M; Repovic P; Riley C; Severson C; Shinnar S; Suski V; Weinstock-Gutman B; Yadav V; Zabeti A
    Contemp Clin Trials; 2016 Sep; 50():166-77. PubMed ID: 27521810
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and Safety of Masitinib in Progressive Forms of Multiple Sclerosis: A Randomized, Phase 3, Clinical Trial.
    Vermersch P; Brieva-Ruiz L; Fox RJ; Paul F; Ramio-Torrenta L; Schwab M; Moussy A; Mansfield C; Hermine O; Maciejowski M;
    Neurol Neuroimmunol Neuroinflamm; 2022 May; 9(3):. PubMed ID: 35190477
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A metformin add-on clinical study in multiple sclerosis to evaluate brain remyelination and neurodegeneration (MACSiMiSE-BRAIN): study protocol for a multi-center randomized placebo controlled clinical trial.
    De Keersmaecker AV; Van Doninck E; Popescu V; Willem L; Cambron M; Laureys G; D' Haeseleer M; Bjerke M; Roelant E; Lemmerling M; D'hooghe MB; Derdelinckx J; Reynders T; Willekens B
    Front Immunol; 2024; 15():1362629. PubMed ID: 38680485
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of dronabinol on progression in progressive multiple sclerosis (CUPID): a randomised, placebo-controlled trial.
    Zajicek J; Ball S; Wright D; Vickery J; Nunn A; Miller D; Cano MG; McManus D; Mallik S; Hobart J;
    Lancet Neurol; 2013 Sep; 12(9):857-865. PubMed ID: 23856559
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study.
    Kappos L; Bar-Or A; Cree BAC; Fox RJ; Giovannoni G; Gold R; Vermersch P; Arnold DL; Arnould S; Scherz T; Wolf C; Wallström E; Dahlke F;
    Lancet; 2018 Mar; 391(10127):1263-1273. PubMed ID: 29576505
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Andrographis paniculata decreases fatigue in patients with relapsing-remitting multiple sclerosis: a 12-month double-blind placebo-controlled pilot study.
    Bertoglio JC; Baumgartner M; Palma R; Ciampi E; Carcamo C; Cáceres DD; Acosta-Jamett G; Hancke JL; Burgos RA
    BMC Neurol; 2016 May; 16():77. PubMed ID: 27215274
    [TBL] [Abstract][Full Text] [Related]  

  • 14. N-Acetyl Cysteine as a Neuroprotective Agent in Progressive Multiple Sclerosis (NACPMS) trial: Study protocol for a randomized, double-blind, placebo-controlled add-on phase 2 trial.
    Schoeps VA; Graves JS; Stern WA; Zhang L; Nourbakhsh B; Mowry EM; Henry RG; Waubant E
    Contemp Clin Trials; 2022 Nov; 122():106941. PubMed ID: 36182028
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epigallocatechin Gallate in Progressive MS: A Randomized, Placebo-Controlled Trial.
    Rust R; Chien C; Scheel M; Brandt AU; Dörr J; Wuerfel J; Klumbies K; Zimmermann H; Lorenz M; Wernecke KD; Bellmann-Strobl J; Paul F
    Neurol Neuroimmunol Neuroinflamm; 2021 May; 8(3):. PubMed ID: 33622766
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized, placebo-controlled, phase 2 trial of laquinimod in primary progressive multiple sclerosis.
    Giovannoni G; Knappertz V; Steinerman JR; Tansy AP; Li T; Krieger S; Uccelli A; Uitdehaag BMJ; Montalban X; Hartung HP; Pia Sormani M; Cree BAC; Lublin F; Barkhof F
    Neurology; 2020 Aug; 95(8):e1027-e1040. PubMed ID: 32651286
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A single-center, randomized, double-blind, placebo-controlled study of interferon beta-1b on primary progressive and transitional multiple sclerosis.
    Montalban X; Sastre-Garriga J; Tintoré M; Brieva L; Aymerich FX; Río J; Porcel J; Borràs C; Nos C; Rovira A
    Mult Scler; 2009 Oct; 15(10):1195-205. PubMed ID: 19797261
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Placebo-Controlled Trial of an Oral BTK Inhibitor in Multiple Sclerosis.
    Montalban X; Arnold DL; Weber MS; Staikov I; Piasecka-Stryczynska K; Willmer J; Martin EC; Dangond F; Syed S; Wolinsky JS;
    N Engl J Med; 2019 Jun; 380(25):2406-2417. PubMed ID: 31075187
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A double-blind, randomized, controlled study of oral pirfenidone for treatment of secondary progressive multiple sclerosis.
    Walker JE; Giri SN; Margolin SB
    Mult Scler; 2005 Apr; 11(2):149-58. PubMed ID: 15794387
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.